Group 1 - The company has received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its innovative biological drug, BL-M11D1, for the treatment of newly diagnosed acute myeloid leukemia (AML) [1] - The clinical trial will evaluate the drug in combination with either cytarabine and daunorubicin or venetoclax and azacitidine [1] - BL-M11D1 is a targeted antibody-drug conjugate (ADC) that shares the same technology platform as another drug, BL-B01D1, and is currently undergoing Phase I clinical trials in the U.S. for relapsed or refractory AML [1]